Neurogene Inc.

NGNE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$32.41-6.52%

2026-09-17

Financials

Valuation Metrics

Neurogene Inc.'s Market Cap is $649M. At end of 2025 it was $436M. Ranked #2688 of 3,121 in US market (top 86%), #1155 of 1,463 on NASDAQ (top 79%), #211 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$649M	US#2,688/3,121 Sec#211/266
Revenue	$0.00	US#2,889/3,121 Sec#196/266
Net Income	$-111M	US—/3,121 Sec—/266
Total Assets	$244M	US#2,964/3,121 Sec#234/266
Net Assets	$217M	US#2,662/3,121 Sec#187/266
Employees	131	US#2,581/3,121 Sec#160/266
Value
P/B	2.99x	US#1,749/3,121 Sec#85/266
FCF Yield	-13.43%	US—/3,121 Sec—/266
Profitability
ROE	-51.17%	US#2,687/3,121 Sec#158/266
ROA	-45.47%	US#2,971/3,121 Sec#201/266
Financial Health
Debt Ratio	12.54%	US#143/3,121 Sec#60/266
Total Debt	$8M	US#2,857/3,121 Sec#206/266
FCF	$-87M	US#2,613/3,121 Sec#134/266
Cash	$112M	US#2,152/3,121 Sec#163/266
Current Ratio	10.64x	US#237/3,121 Sec#74/266
Performance
1Y Return	83.00%	US#284/3,121 Sec#74/266
1M Return	-9.14%	US#2,352/3,121 Sec#177/266
From 52W High	-25.77%	US#1,828/3,121 Sec#141/266
1Y MDD	-52.37%	US#2,546/3,121 Sec#189/266
Trading
Volume	169,378 shares	US#2,728/3,121 Sec#255/266
Trading Value	$6M	US#2,615/3,121 Sec#217/266
Per Share
EPS	$-5.55	US—/3,121 Sec—/266
BPS	$10.85	US#1,790/3,121 Sec#69/266

Company Info

CEO Rachel L. McMinn

Employees 131

HQ New York City, US

Website https://www.neurogene.com

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.